Concepedia

Nancy S. Scher

NS

Statistics

Publications

6

Citations

538

H-Index

6

Active since

1976

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Nancy S. Scher is an author at United States Food and Drug Administration specializing in pharmacotherapy, cancer therapeutics, and medicine.

Top concepts

Publications per year

1976–2018

6

Publications

6

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Amna Ibrahim, Nancy S. Scher, Grant Williams et al. · PubMed · 2003 · 198 citations

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

Gideon M. Blumenthal, Nancy S. Scher, Patricia Cortazar et al. · Clinical Cancer Research · 2013 · 116 citations

, , +11

End points to establish the efficacy of new agents in the treatment of acute leukemia

Frederick R. Appelbaum, Daniel Rosenblum, R.J. Arceci et al. · Blood · 2006 · 91 citations · Full text

FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer

Lynn Howie, Nancy S. Scher, Laleh Amiri‐Kordestani et al. · Clinical Cancer Research · 2018 · 66 citations

U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid

Martin H. Cohen, Ramzi Dagher, Donna Griebel et al. · The Oncologist · 2002 · 56 citations · Full text

, , +16

Rows per page

1–5 of 6